Nuwellis Expands Aquadex Console Sales, Boosting Recurring Revenue Potential
Event summary
- Nuwellis sold 31 Aquadex SmartFlow consoles year-to-date in 2026, exceeding full-year sales in seven of the past 10 years.
- U.S. revenue grew 26% year-over-year in the first half of 2026 across pediatrics, critical care, and heart failure markets.
- Each console expands the installed base, driving recurring revenue from single-use blood circuits.
- Performance reflects normalized hospital environment adoption, not COVID-19-driven demand.
The big picture
Nuwellis' strong console sales and revenue growth signal growing acceptance of the Aquadex SmartFlow system in normalized hospital settings. The company is positioning itself to build a more durable recurring-revenue business by expanding its installed base and increasing consumable utilization. This trend reflects broader industry shifts towards advanced fluid-management solutions in critical care.
What we're watching
- Console Adoption
- Whether Nuwellis can sustain the current pace of console sales through the remainder of 2026.
- Recurring Revenue
- How the expanding installed base will translate into increased consumable utilization and revenue.
- Market Expansion
- The pace at which Nuwellis can broaden adoption of Aquadex therapy across its core markets.
Related topics